Influence of Ca2+ and pH on the folding of the prourotensin II precursor  by Bilodeau, Josée et al.
FEBS Letters 585 (2011) 1910–1914journal homepage: www.FEBSLetters .orgInﬂuence of Ca2+ and pH on the folding of the prourotensin II precursor
Josée Bilodeau 1, Antoine Désilets 1, François-Olivier McDuff, Caroline St-Pierre, Élie Barbar, Richard Leduc ⇑,
Pierre Lavigne ⇑
Department of Pharmacology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada J1H5N4
a r t i c l e i n f o a b s t r a c tArticle history:
Received 9 February 2011
Revised 21 April 2011
Accepted 27 April 2011
Available online 19 May 2011





Protein folding0014-5793/$36.00  2011 Federation of European Bio
doi:10.1016/j.febslet.2011.04.075
Abbreviations: ProUII, prourotensin II; PC1/3, pr
proprotein convertase 2; IPTG, isopropyl-b-D-1-th
guanidine hydrochloride; TCEP, tris(2-carboxyethy
dichroism
⇑ Corresponding authors. Address: Department o
Medicine and Health Sciences, Université de Sherbroo
Sherbrooke, Quebec Canada J1H 5N4.
E-mail addresses: Richard.Leduc@USherbrook
Lavigne@USherbrooke.ca (P. Lavigne).
1 These authors contributed equally to the work.Proper folding is a crucial step for the trafﬁcking of proteins through the secretory pathway. We
hypothesized that the secretory granules of endocrine cells provide optimal folding conditions of
prohormone precursors for cleavage. Here, using circular dichroism and in vitro processing on puri-
ﬁed prourotensin II (ProUII), we show that the precursor undergoes pH- and Ca2+-dependent confor-
mational and stability changes. ProUII has a stable tertiary structure at pH 5.5 in presence of Ca2+
and is correctly cleaved in these conditions by prohormone convertases. Taken together, our results
support the notion that precursors may need to be optimally folded in the lumen of secretory gran-
ules for their processing.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Up to a third of translated proteins in eukaryotic cells enter the
secretory pathway and many of these that trafﬁc through this
pathway are initially biosynthesized as inactive precursor proteins
that undergo obligatory proteolytic cleavage in order to generate a
multitude of biologically active peptides. Although this process
takes place in all cell types and is mostly under the control of a
family of serine proteases termedmammalian secretory proprotein
convertases, in endocrine or neuroendocrine cells maturation of
prohormone precursors is almost exclusively achieved by the pro-
protein convertase 1 (PC1/3) and proprotein convertase 2 (PC2)
within dense core secretory granules [1,2]. It is in these organelles
that the two convertases are activated and that they catalytically
cleave their substrates at speciﬁc basic residues. Indeed, the ma-
ture and active forms of PC1/3 and PC2 are optimally active at
acidic pH (between 5.5 and 6.5 for PC1 and 5 for PC2) and in pres-
ence of Ca2+ ions [3,4]. Although the conditions that prevail in thechemical Societies. Published by E
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olytic activity of the convertases, it’s not clear if this environment
affects the stability of their precursor substrates and the accessibil-
ity of the recognized and processed peptide bond.
One of the simplest model systems for a prohormone precursor
is urotensin II (UII) [5]. The UII gene encodes a single-chain precur-
sor preproUII (124 amino acids) that undergoes an initial proteo-
lytic step to remove a signal peptide upon translocation of the
polypeptide chain in the lumen of the endoplasmic reticulum.
The resulting 104-residue prourotensin II (proUII) (isoform 1), for
which the three-dimensional structure has yet to be determined,
contains the biologically undecapeptide urotensin II (UII) located
completely at its C-terminus, following a Lys-Lys-Arg prohormone
convertase recognition sequence at position 111–113. In endocrine
and neuroendocrine cells, proUII is further processed presumably
by PC1/3 or PC2 and the hormone, UII, is then released from the cell
following an appropriate stimulus. Indeed, Chartrel et al. have
determined that intact UII is found in motoneurons directly dem-
onstrating that processing of proUII does occur at the Lys-Lys-
Arg; cleavage site [6]. Because proUII has also been detected in
non-endocrine or non-neuroendocrine cells [7,8], it is possible that
other proteases, of the convertase or other protease families, are
involved in the processing of this precursor. Moreover, although
proUII contains other putative cleavage sites than the biologically
relevant Lys-Lys-Arg113 – such as the Arg-Lys70 and Arg-Lys86 sites
and single basic residues – it also remains to be determined if the
precursor is further processed into active peptides other than UII.lsevier B.V. All rights reserved.
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in the medulla oblongata, in kidney and in many other tissues in
humans [7,9]. Both PC1/3 and PC2 are also expressed in many
but not all these tissues [10,11]. Apart from its well-recognized
role as a vasoactive peptide [12], it has also been reported that
UII is involved in sensory-motor integration in the nervous system
[13] and as a chemotactic factor in monocytes [14]. The released
bioactive UII exerts its biological effects through binding to the
UT receptor, a member of the G protein coupled receptor family
[15,16], also widely expressed in the central nervous system.
Thus, our objective was to analyze whether this precursor’s
structure was affected in different basic conditions of pH and
Ca2+, environments in which the protein resides when trafﬁcking
occurs from the ER to the Golgi and to the secretory granule in
endocrine and neuroendrocrine cell types. We therefore expressed,
puriﬁed and characterized the overall secondary structure of
proUII by circular dichroism (CD) and showed that the precursor
is stably folded in the presence of Ca2+ ions and at pH 5.5, poten-
tially facilitating its cleavage by neuroendocrine PC1/3 and PC2
in the regulated secretory pathway. We also demonstrate that
PC1/3 and PC2 correctly cleave the precursor, releasing the bioac-
tive UII moiety.
2. Materials and methods
2.1. Expression of proUII
The Escherichia coli strain Rosetta-gamiB(DE3)pLysS (EMD
Chemicals, Gibbstown, NJ) was transformed with expression plas-
mid pET19b (EMD Chemicals) containing the human proUII cDNA
(Refseq No. NP_006777.1) without its signal peptide (residues
21–124) and with an N-Terminal Met-Gly sequence followed by
a 6 X His tag for puriﬁcation. Pre-cultures (10 ml) were grown
overnight at 37 C in LB supplemented with antibiotics (50 mg/
ml of ampicilin and 34 mg/ml of chloramphenicol). The cultures
were transferred to fresh LB (1 l) supplemented with the same
antibiotics. Expression of the proUII construct was induced by
the addition of 0.6 M isopropyl-b-D-1-thiogalactopyranoside (IPTG)
at about mid-log phase (OD600 nm 0.6). The culture was main-
tained at 37 C for 4 h. Cells were harvested by centrifugation at
5000 rpm for 10 min at 4 C in a Sorvall RC-5B using a SLA-1500 ro-
tor. Bacterial pellets were then frozen and stored at 20 C prior to
puriﬁcation.
2.2. Puriﬁcation of proUII
The harvested bacterial pellets (from 1 l culture) were resus-
pended in 10 ml of lysis buffer (10 mM Tris–HCl pH 7.6, 0.5 mM
CaCl2, 2.5 mMMgCl2), vortexed and lysed by sonication on ice. Tri-
ton X-100 (1%) and DNAse (0.04 mg/ml) were then added to the
sonicated mixture and incubated for 30 min at 37 C. The inclusion
bodies were pelleted by centrifugation at 15 000 rpm for 30 min at
4 C and resuspended with 15 ml of a chaotropic buffer (3 M urea,
100 mM NaAc, 500 mM guanidine hydrochloride (GnHCl) at pH 5)
and incubated for 30 min at 37 C. Then, 15 mL of a 2 M urea solu-
tion was added and the inclusion bodies were collected by centri-
fugation (15 000 rpm) for 30 min at 4 C. The inclusion bodies were
solubilized with 10 ml of a solution containing 8 M urea (pH 7.5),
100 mM Na2HPO4, 100 mM KH2PO4, 100 mM KCl and 5 mM
tris(2-carboxyethyl)phosphine (TCEP) and stored at 4 C overnight.
The inclusion body fraction was further centrifuged (4500 rpm)
30 min at 4 C and the supernatant was ﬁltered with a syringe
through a 22-l ﬁlter. 1/5th of the supernatant was loaded onto a
column packed with 2 mL of Ni–NTA (Bio-Rad) resin which was
pre-equilibrated with a binding Buffer (100 mM Na2HPO4,100 mM KH2PO4, 100 mM KCl, 5 mM TCEP, pH 7.5, 50 mM imidaz-
ole) and allowed to bind for 2 h at 20 C with gentle shaking. Two
washes (one column volume (CV) each) were done with buffer 1
(binding buffer plus 8 M urea pH 7.5). Ten washes with half CV
with washing buffer 2 (binding buffer with no urea and no TCEP
pH 7.5) were necessary to gradually decrease and completely re-
move the urea and TCEP. This procedure allowed for the formation
of the intramolecular C-terminal disulﬁde bond on the resin. The
use of higher protein to resin ratio and the oxidation of proUII in
solution led to the formation of multimeric species most likely
through the formation of inter-molecular disulﬁde bonds. Such
oligomers were not observable on SDS–PAGE in absence of reduc-
ing agents when low ratios were used.
The folded proUII was eluted from the column with 10 ml of
elution buffer (100 mM Na2HPO4, 100 mM KH2PO4, 100 mM KCl
and 300 mM imidazole pH 7.5), transferred in Amicon centrifugal
ﬁlters of 3 kDa molecular weight cut-off (Millipore, Billerica, MA,
USA) and centrifuged for 20 min (4500 rpm) at 15 C to allow for
the exchange of buffer. The protein was washed ﬁve times in the
centrifugal ﬁlters with the CD buffer (25 mM KH2PO4, 25 mM
KCl) at the desired pH (5.5, 6.5 and 7.5) with and without CaCl2
(100 lM). Protein concentrations were determined by measuring
absorbance at 280 nm using an extinction coefﬁcient of
13 980 M1 cm1.
2.3. Circular dichroism spectropolarimetry
CD measurements were performed using a Jasco J-810 spectro-
polarimeter equipped with a Jasco Peltier-type thermostat as pre-
viously described [17]. The instrument was calibrated routinely
with aqueous solution of D-10(+)-camphor–sulfonic acid at
290.5 nm. The samples were loaded into 0.1 cm path-length quartz
cells. All CD spectra and temperature denaturation measurements
were recorded at identical protein concentrations (32 lM). Spectra
were recorded at 20 C temperatures from 300 nm to 195 nm by
accumulating ﬁve scans at 0.1 nm intervals. Thermal denaturations
were performed from 5 to 95 C at rate of 1 C/min and were re-
corded at 222 nm.
The raw data in mdeg (H) were transformed in molar ellipticity
([H], deg cm2 dmol1) using the following equation: [H] =H (in
deg) MRW/10 path length (cm)  concentration (g/ml); where
MRW is the mean residue weight (molecular weight (131 000
(g/mol)/number of residues (111)). Finally, the % of a-helical struc-
ture was determined with the empirical equation proposed by
Morrow et al. [18]: % a-helix = ([H]222 nm + 3000)/39 000, where
[H]222 nm is the molar ellipticity at 222 nm.
2.4. In vitro cleavage of proUII by prohormone convertases
Recombinant mouse PC1/3 and PC2 proteins were a generous
gift from Dr. Iris Lindberg and were puriﬁed as described [19].
The proteases were active-site titrated using Decanoyl-Arg-Val-
Lys-Arg-CMK (Axxora LLC, San Diego, CA, USA). ProUII (5 lM)
and enzyme (0, 12.5, 25, 50 and 100 nM) were incubated for 16 h
at 37 C in Assay buffer (100 mM sodium acetate, 0.1% Brij,
0.1 mg/ml BSA, 2 mM CaCl2 and 0.1% NaN3). Proteins were sepa-
rated on a 16.5% SDS–PAGE and revealed using Gel Code blue stain
reagent (Pierce, Rockford, IL, USA).
3. Results and discussion
3.1. Expression and puriﬁcation of the proUII construct
To examine the effect of pH and Ca2+ on the stability and folding
of proUII, we expressed and puriﬁed an N-terminal tagged,
Fig. 1. Expression and puriﬁcation of proUII. (A) Schematic representation of
recombinant human proUII. The protein is composed of a Met-Gly sequence
followed by a 6 X His tag and proUII (isoform1, residues 21–124) without the signal
peptide. The carboxy-terminal bioactive UII peptide is represented by a dark box
and the putative cleavage site (LysArgArg113) is indicated by an arrow. (B) Rosetta
Gami B strains were transformed with the proUII-pet19b construct and expression
induced with 0.6 mM IPTG. Samples taken during the puriﬁcation process were
resolved by SDS–PAGE and stained with Coomassie blue (1, molecular weight
marker; 2, non-induced bacterial lysate; 3, induced bacterial lysate; 4, inclusion
bodies; 5, puriﬁed proUII).
Fig. 2. The proUII secondary structure content is favored at pH 6.5, without calcium
but importantly at pH 5.5 with calcium. Far-UV CD spectra of proUII in absence (A)
and presence (B) of calcium, respectively at pH 7.5 (long dashes), 6.5 (solid line) and
5.5 (short dashes). The minima observed at 208 and 222 nm suggest that proUII
possesses a signiﬁcant amount a-helical structure (see text for details). In
conditions prevailing in the secretory granules (low pH and signiﬁcant calcium
concentration), proUII would have an optimal helical content.
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used, we removed the signal peptide from the precursor, which
then consisted of a Met-Gly-His-His-His-His-His-His sequence fol-
lowed by amino acids 21–124 of proUII (Fig. 1A). The protein accu-
mulated in inclusion bodies of bacteria and needed to be refolded
on the nickel afﬁnity column. As can be seen on Fig. 1B, a signiﬁ-
cant increase of a band at 13.1 kDa corresponding to proUII is ob-
served (compare lanes 2 and 3) after a 4 h induction with IPTG at
37 C to the growing bacterial culture. ProUII was present in the
solubilized inclusion bodies (lane 4), which was then puriﬁed to
homogeneity (lane 5).
3.2. Characterization of the overall folding of proUII by circular
dichroism
In their transit from the ER to the secretory vesicles, prohor-
mone precursors experience an acidiﬁcation gradient from 7.0
to 5.5 and are exposed to calcium [20]. In order to monitor how
the secondary and tertiary structures of proUII respond to these
conditions, we recorded far-UV CD spectra (Fig. 2) and monitored
temperature denaturations (Fig. 3). Importantly, analysis of several
His-tag proteins has shown that the epitope tag is rarely involved
in tertiary interactions and that overall structures are not affected
by its presence [21].
Fig. 2 depicts the Far-UV CD spectra of proUII at pH 7.5, 6.5 and
5.5 in absence (A) and presence (B) of calcium (0.1 mM), respec-
tively. In the absence of calcium, the CD spectrum of proUII at
7.5 is indicative of a protein with a signiﬁcant a-helical content
with apparent minima at 208 and 222 nm [22]. From the molar
ellipticity at 222 nm ([H]222 nm) an a-helix percentage of 23% can
be calculated (see Section 2). Judging by the more negative molarellipticity at 222 nm, this a-helical content is increased to 33% at
pH 6.5. However, lowering the pH from 6.5 to 5.5 in absence of cal-
cium leads to signiﬁcant decrease in secondary structure with a
residual a-helical percentage of 17. Indeed, the higher ellipticity
at 222 nm and the minimum at 204 nm is indicative of a higher
content of irregular structure [22]. Interestingly, acidiﬁcation in
the presence of calcium (Fig. 2B) drastically affected the secondary
structure of proUII. In fact, the helical content at pH 7.5 was in-
creased (from 23% to 28%) and that at 6.5 was reduced from 33%
to 30%. Finally, we found that proUII, at pH 5.5 and in the presence
of calcium had the largest amount of secondary structure with an
a-helical content of 36%.
The temperature denaturation of proUII at pH 5.5, 6.5 and 7.5 in
absence (A) and in presence (B) of calcium are shown in Fig. 3. In
the absence of calcium and at pH 7.5, proUII displays a shallow
denaturation proﬁle with an apparent T around 47.5 C. Also note
the more persistent negative molar ellipticity beyond the transi-
tion compared to the other two curves. The largest extent of sec-
ondary structure observed at pH 6.5 (Fig. 2A) correlates with the
Fig. 3. The proUII tertiary structure content is favored at pH 6.5, without calcium
and at pH 5.5 in presence of calcium. Temperature denaturations monitored by CD
of proUII in absence (A) and in presence (B) of calcium, respectively at pH 7.5 (open
circles), 6.5 (ﬁlled circles) and 5.5 (open squares). pH is modulating both the
‘‘native’’ and ‘‘denatured’’ states of proUII in presence and absence of calcium. Most
importantly, in conditions prevailing in the secretory granules (acidic pH with
calcium, i.e. pH 5.5 in B), proUII would be stably folded.
Fig. 4. PC1/3 and PC2 cleavage of proUII. Increasing concentrations of puriﬁed
recombinant and titrated PC1/3 or PC2 were incubated with a ﬁxed amount of
proUII. From left to right: stoichiometric substrate/enzyme ratio of 0, 1/400, 1/200,
1/100 and 1/50 were used. Reactions were performed for 16 h at 37 C at the
indicated pH in presence of 2 mM Ca2+. Proteins were separated on a 16.5% SDS–
PAGE and visualized using Gel Code blue stain reagent (Pierce).
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Such large amplitude in the denaturation curve indicates a large
content of enthalpy or favorable tertiary and secondary interac-
tions and the achievement of a mostly unstructured denatured
state. Finally, despite having the highest content of irregular struc-
ture, proUII at pH 5.5 displays a clear transition with an apparent T
of 55 C, indicating a signiﬁcant content of stable tertiary structure.
Overall these data indicate a complex pH dependence of the sec-
ondary and tertiary structure content of proUII. Indeed, it appears
that pH modulates the secondary structure of the ‘‘native’’ and
‘‘denatured states’’ of proUII in the absence of calcium. Interest-
ingly, in the presence of calcium, the apparent T (55 C) of the
transition at all pH values is identical (Fig. 3B). However, one can
observe that the amplitude of the transitions increase as the pH
is decreased from 7.5 to 5.5. This demonstrates that the amount
of tertiary interactions, in the presence of Ca2+ ions, is maximalat pH 5.5. Although the three-dimensional structure of proUII has
yet to be determined, our results indicate that the precursor is
optimally folded under these conditions.
3.3. In vitro cleavage of proUII by PC1/3 and PC2
The pH- and Ca2+-dependent effects observed on proUII folding
prompted us to further explore the processing of the precursor by
incubating it with the neuroendocrine PC1/3 and PC2 [19] in vitro
and analysing the resulting cleavage proﬁle by SDS–PAGE. To eval-
uate the effect of pH on proUII processing, we performed cleavage
assays in presence of Ca2+ at pH 7.5, 6.5 and 5.5 using puriﬁed re-
combinant proUII incubated with titrated, PC1/3 and PC2. Overall,
as shown in Fig. 4, proUII migrates at 13.1 kDa and incubation with
either of the convertases in acidic conditions led to the appearance
of a band corresponding to processed proUII or propeptide (resi-
dues 21–113) with an apparent molecular weight of 11.7 kDa, a
difference corresponding to the release of the UII peptide
(1.4 kDa). Samples were analyzed by mass spectroscopy (results
not shown) which conﬁrmed that processing occurred at the
Lys-Arg-Arg113 cleavage site by detection of the 1.4 kDa UII. In
depth analysis revealed that although a very faint band appeared
at pH 7.5, we conclude that processing is quite inefﬁcient at this
pH even with increasing concentrations of either PC1/3 or PC2.
Incubating the reaction mixture at 6.5, we observed a higher inten-
sity of the band at 11.7 kDa (corresponding to the 21–113 frag-
ment) with increasing levels of PC1/3 but less with PC2. At pH
5.5, a near complete cleavage of proUII occurred with PC1/3 (using
a stoichiometric ratio of 1/50, last lane) while partial cleavage was
obtained with PC2. In line with the fact that the neuroendocrine
convertases PC1/3 and PC2 exhibit optimal activities at acidic pH
(between 5 and 6.5), we clearly demonstrate that proUII is cleaved
at the Lys-Arg-Arg113 processing site by PC1/3 and PC2 yielding the
UII peptide, a process that is pH-dependent at least in vitro.
Therefore, efﬁcient cleavage of proUII at pH 5.5 could be the result
of a combination of factors; optimal enzymatic activities of conver-
tases and proper folding of proUII. It is, however, premature to
state whether PC1/3 and/or PC2 are the only bona ﬁde proUII con-
vertases or whether other proteases might also cleave the precur-
sor. This is particularly important considering that proUII is also
expressed in non-endocrine tissues [7,8]. To address this issue
we also incubated proUII with the constitutively expressed conver-
tase furin but, in our conditions, failed to detect cleavage of the
precursor (data not shown). This was expected since proUII does
not contain an Arg in the P4 position of the processing site, a
1914 J. Bilodeau et al. / FEBS Letters 585 (2011) 1910–1914determinant that furin prefers for cleavage. Other constitutively
expressed convertases (or other proteases) may therefore be
responsible for processing of proUII in those non-neuronal tissues.
Few studies have examined the structure and folding of prohor-
mone precursors. The processing of prohormone precursors in gen-
eral may depend on multiple factors such as optimal conditions for
(1) folding of the precursor substrate and (2) proteolytic activity of
the converting enzyme. Both of these factors would be crucial for
the accessibility of the correct processing site vs. other potential
sites that are not cleaved by the proteases. Indeed, although the
proUII precursor is a simple one when looking at the potential rec-
ognition and cleavage sites, there are other pairs of basic amino
acids and single basic amino acids that remained uncleaved in
our in vitro conditions. Perhaps the inaccessibility of these sites
by the proteases acts as a regulatory step in the speciﬁcity of the
processing event. Moreover, molecular determinants found in var-
ious regions of other prohormone precursor molecules, such as
proinsulin, have been shown to play a role in folding. Indeed,
mutations within an N-terminal hydrophobic sequence of proinsu-
lin can cause multiple effects on the efﬁciency of folding of the pre-
cursor [23].
The conversion of proUII to UII in neuroendocrine cells most
likely occurs through the maturation from the trans-Golgi network
to the secretory granules. Since the tissue speciﬁc expression of the
UII gene coincides with the expression of the pro-protein conver-
tases PC1/3 and PC2 we believe that one of these are the bona ﬁde
proUII convertase in neuroendocrine and neuronal cells. The ma-
ture and active form of these enzymes is found in an acidic and
Ca2+-rich environment such as those that prevail in the secretory
granules. As observed for proinsulin [24], this environment may fa-
vor the formation of enzyme-substrate complexes through confor-
mational changes.
Taken together, our results suggest that the acidic microenvi-
ronment typical of the mature secretory granules promotes an
optimal conformation for proUII processing. This environment-
dependent susceptibility for cleavage confers a regulation mecha-
nism of proUII processing and thus of UII signaling.
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